Previous 10 | Next 10 |
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 PR Newswire NEWARK, Calif. , May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first hu...
Protagonist Therapeutics ([[PTGX]] +3.4%) is trading higher today after announcing that an abstract with updated data from its ongoing Phase 2 study for rusfertide in polycythemia vera ("PV") has been selected for an oral presentation at a major medical meeting.The presentation titl...
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Updated Phase 2 analysis to be presented by Dr. Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai P...
Protagonist (PTGX): Q1 GAAP EPS of -$0.54 beats by $0.03.Revenue of $6.19M (+69.6% Y/Y) beats by $4.69M.Press Release For further details see: Protagonist EPS beats by $0.03, beats on revenue
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update PR Newswire NEWARK, Calif. , May 4, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first...
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting -- Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythe...
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide ...
Protagonist Therapeutics, Inc. (PTGX) Q4 2020 Earnings Conference Call March 10, 2021 16:30 ET Company Participants Dinesh Patel - President and Chief Executive Officer Don Kalkofen - Chief Financial Officer Samuel Saks - Chief Medical Officer David Liu - Chief Scientific Officer Suneel Gupta...
Protagonist (PTGX): Q4 GAAP EPS of -$0.48 in-line.Revenue of $5.65M (+107.7% Y/Y) beats by $2.95M.Company expects to share findings from ongoing hereditary hemochromatosis study for rusfertide (PTG-300) in the second half of 2021.Cash, cash equivalents and marketable securities as of December...
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update -- Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia ver...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...